MIPLYFFA
Growtharimoclomol citrate
NDAORALCAPSULEPriority Review
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIPLYFFA (arimoclomol citrate) is an oral capsule approved by FDA on September 20, 2024, for the treatment of neurological conditions. The drug acts as a heat shock protein (HSP) co-inducer, enhancing cellular stress response pathways. It represents a novel mechanism to address protein misfolding diseases.
Growth15.3 years to LOE
Recent approval positions this product in early growth phase with opportunity for team expansion and market penetration strategy development.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MIPLYFFA represents an early-stage, recently approved small molecule with zero competitive threats and a 15+ year patent runway, creating strategic value for professionals entering or advancing in Medical Affairs and Medical Leadership roles. The uncontested market position and growth phase lifecycle signal opportunity for building brand presence, clinical evidence generation, and indication expansion strategies with long-term job stability.
Medical Director
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.